ATG-102

N/A

Report date: 2024/08/29 15:58:50

Base Information

Drug NameATG-102
Drug Alias NameATG-102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 4 inhibitorsT cell surface glycoprotein CD3 modulators
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4T cell surface glycoprotein CD3
Therapy Area/IndicationsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAntengene Corporation Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAntengene Corp LtdAntengene Corporation Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A